Abstract
The disclosure provides a versatile method termed CRISPR-SKIP that utilizes cytidine and/or adenine deaminase base editors to program exon skipping by mutating target DNA bases within splice acceptor sites and/or splice enhancer sites. Given its simplicity and precision, CRISPR-SKIP will be broadly applicable in gene therapy and synthetic biology.
| Original language | English (US) |
|---|---|
| U.S. patent number | 12612612 |
| Filing date | 6/19/19 |
| State | Published - Apr 28 2026 |
Fingerprint
Dive into the research topics of 'Methods for exon skipping and gene knockout using base editors'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS